40 results
8-K
EX-99.1
APLS
Apellis Pharmaceuticals Inc
5 Oct 23
Apellis Announces Preliminary U.S. Net Revenues of Approximately $74 Million for SYFOVRE® (pegcetacoplan injection) in the Third Quarter of 2023
7:15am
that occurred in mid-August and one in September. Of the two events that were previously classified as suspected, one event has been confirmed
424B5
ciytpb6n
24 Mar 22
Prospectus supplement for primary offering
8:02pm
424B5
pbzhby
23 Mar 22
Prospectus supplement for primary offering
5:14pm
424B5
uyxoqw03deckwb7
17 Nov 21
Prospectus supplement for primary offering
9:02am
424B5
hjvdel
15 Nov 21
Prospectus supplement for primary offering
5:24pm